Health Canada
EVENT
Advisory Committee: Implementation Advisory Group (IAG) for the National Strategy for Drugs for Rare Diseases
Published: 11/16/2026Detected: 3/19/2026
Summary preview
Establishes and supports an Implementation Advisory Group (IAG) to coordinate Health Canada’s implementation of the National Strategy for Drugs for Rare Diseases, potentially shaping how rare-disease drug development…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountrare_diseases
clinical
safety
quality
labeling
manufacturing
#Health Canada
#advisory committee
#Implementation Advisory Group
#rare diseases
#National Strategy for Drugs for Rare Diseases
Official Source Document Source Verified
Access the original document directly from HEALTH CANADA.
More from Health Canada
- Advisory Committee: Review of the Federal Approach to Pandemic Science Advice and Research Coordination11/16/2026
- Advisory Committee: National Pharmacare Committee of Experts11/16/2026
- Advisory Committee: Ministerial Advisory Council on Mental Health11/16/2026
- Advisory Committee: Expert Task Force on Substance Use11/16/2026
- Advisory Committee: Expert Panel on MAID and Mental Illness11/16/2026